StockNews.com Initiates Coverage on Agile Therapeutics (NASDAQ:AGRX)

Equities research analysts at StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a report issued on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Stock Performance

AGRX stock opened at $1.46 on Friday. The stock has a market capitalization of $10.01 million, a P/E ratio of -0.40 and a beta of 1.58. Agile Therapeutics has a 12 month low of $0.20 and a 12 month high of $2.63. The firm has a 50-day moving average price of $1.20 and a 200-day moving average price of $0.80.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings data on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter. The company had revenue of $5.58 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC lifted its stake in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the quarter. Armistice Capital LLC owned about 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.